Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines

This publication has 54 references indexed in Scilit:

• Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving Hemodialysis
  New England Journal of Medicine, 2002
• Capsule Production and Growth Phase Influence Binding of Complement toStaphylococcus aureus
  Infection and Immunity, 2001
• Clostridium difficile Recombinant Toxin A Repeating Units as a Carrier Protein for Conjugate Vaccines: Studies of Pneumococcal Type 14, Escherichia coli K1, and Shigella flexneri Type 2a Polysaccharides in Mice
  Infection and Immunity, 2000
• Prevention of Systemic Infections Caused by Group B Streptococcus and Staphylococcus aureus by Multivalent Polysaccharide‐Protein Conjugate Vaccines
  Annals of the New York Academy of Sciences, 1995
• Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines
  The Journal of Pediatrics, 1995
• Depressed Phagocytosis in Hemodialyzed Patients: In vivo and in vitro Mechanisms
  Nephron, 1993
• Staphylococcus aureus
  New England Journal of Medicine, 1984
• Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus
  Diagnostic Microbiology and Infectious Disease, 1984
• Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates
  Journal of Infection, 1981
• Bacteremia at Boston City Hospital: Occurrence and Mortality during 12 Selected Years (1935-1972), with Special Reference to Hospital-Acquired Cases
  The Journal of Infectious Diseases, 1975